Gilead Sciences (GILD) Convertible Debt (2009 - 2010)
Gilead Sciences' (GILD) quarterly Convertible Debt came in at $2.8 billion in Q4 2010, up 145.67% YoY from $1.2 billion in Q4 2009, and up 0.7% on a QoQ basis from $2.8 billion in Q3 2010.
Gilead Sciences (GILD) Convertible Debt (2009 - 2010) Analysis & Trends
Gilead Sciences (GILD) has 2 years of Convertible Debt data on file, last reported at $2.8 billion in Q4 2010.
- Quarterly Convertible Debt rose 145.67% year-over-year to $2.8 billion in Q4 2010, while the trailing twelve-month figure through Dec 2010 was $2.8 billion (up 145.67% YoY) and the FY2010 annual result came in at $2.8 billion, up 145.67% from the prior year.
- Convertible Debt improved to $2.8 billion in Q4 2010, from $2.8 billion in the prior quarter.
- In the past five years, Convertible Debt ranged from a high of $2.8 billion in Q4 2010 to a low of $1.1 billion in Q2 2009.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2010 | 2.84 Bn |
| Sep 30, 2010 | 2.82 Bn |
| Mar 31, 2010 | 1.17 Bn |
| Dec 31, 2009 | 1.16 Bn |
| Sep 30, 2009 | 1.14 Bn |
| Jun 30, 2009 | 1.13 Bn |